Ocugen, Inc. announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). Mrs. Johnson-Greene has more than 20 years of healthcare experience. She most recently served as Chief Operating Officer at the Alliance for Regenerative Medicine (ARM) where she led ARM's operations, finance, and global expansion initiatives to advance the development of engineered cell therapies and genetic medicines and promote access for all patients.
Prior to her role at ARM, she was the Vice President of Sales and Qualified Treatment Centers (QTC) at Genetix Biotherapeutics (formerly known as bluebird bio), where she built and scaled pre-commercial U.S. sales and QTC operations teams to support the launch of the ZYNTEGLO and SKYSONA gene therapy brands. Mrs. Johnson-Greene also held senior leadership positions at Spark Therapeutics and supported the launch of LUXTERNA. Previously, she held roles in finance, commercial operations, and sales in both North and South America for AstraZeneca.
Mrs. Johnson-Greene began her career in strategic consulting with Accenture?s strategy practice. Mrs. Johnson-Greene earned her MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania, and her undergraduate degree in Electrical Computer Engineering from Drexel University. She serves on the Drexel University Biomed Dean's Executive Advisory Council and is a guest lecturer for biomedical graduate students.
